Submit an Article
Navigate
Home
Editorial Board
Editorial Policies
Current Volume
Archive
Scientific Integrity
Publication Ethics Statements
Interviews with Outstanding Authors
Newsroom
Sponsored Conferences
Podcast
Contact
Special Collections
Submit an Article
Online ISSN: 1945-4589
Research Paper
|
Volume 16, Issue 4
|
pp. 3631–3646
The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma
Back to article
Figure 2
(2 of 3)
−
100%
+
Figure 2.
Comparison of survival between FH-dRCC patients and T2 pRCC.
(
A
) DFS of FH-dRCC and T2 pRCC; (
B
) CSS of FH-dRCC and T2 pRCC).
